View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAtreca 将来の成長Future 基準チェック /06 Atrecaは収益が増加すると予測されています。主要情報4.3%収益成長率n/aEPS成長率Biotechs 収益成長22.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジLow最終更新日31 May 2024今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 06Atreca, Inc. Announces Resignation of Franklin Berger from the BoardOn May 13, 2024, Mr. Franklin Berger resigned from the board of Atreca, Inc. Accordingly, Mr. Berger now serves on the boards of directors of three other public companies in addition to the Atea Board (Satellos Bioscience Inc., ESSA Pharma Inc., and Kezar Life Sciences, Inc.).お知らせ • May 21Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) for $12.5 million on December 22, 2023. Pursuant to the agreement, Immunome will pay an aggregate purchase price of up to $12.5 million in cash, with $5.5 million due to the Atreca at the closing of the agreemeny and up to $7 million due upon the achievement of certain clinical-based milestone. The agreement have been unanimously approved by the board of directors of the Atreca. The agreement must also be approved by the Atreca’s stockholders, as a condition to the closing. In certain circumtances Atreca will pay a termination fee of $0.5 million to Immunome. Transaction is expected to close in the second quarter of 2024. John T. McKenna and Matthew Silverman of Cooley LLP acted as legal advisor to Atreca. Kingsley Taft and Steven Green of Goodwin Procter LLP acted as legal advisor to Immunome.Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) on May 20, 2024.お知らせ • Apr 02Atreca, Inc. Files Form 15Atreca, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Class A Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Class A Common Stock was $0.0001 per share.お知らせ • Mar 21Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI IndexAtreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Indexお知らせ • Mar 19Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite IndexAtreca, Inc. has been dropped from NASDAQ Composite Index .お知らせ • Mar 12Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid RequirementAs previously reported, on September 8, 2023, Atreca, Inc. (the Company") received written notification (the Initial Notice") from The Nasdaq Stock Market LLC (Nasdaq") notifying it that on September 7, 2023, the average closing price of the Company's Class A common stock, $0.0001 par value per share (the Class A Common Stock"), over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days from the date of the Initial Notice, or March 6, 2024, to regain compliance with the Minimum Bid Requirement (the Grace Period"), subject to a potential 180-day extension. To regain compliance, the closing bid price of the Class A Common Stock must have been at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period. On March 8, 2024, the Company received written notification from Nasdaq indicating that it had failed to achieve compliance with the Minimum Bid Requirement prior to the expiration of the Grace Period, and therefore the Class A Common Stock will be delisted from trading on Nasdaq. The Company does not intend to request an extension of the Grace Period or any administrative hearing to delay such delisting. As a result, the Class A Common Stock will be suspended from trading at the opening of business on March 19, 2024. Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission (the SEC") to remove the Class A Common Stock from listing and registration, though Nasdaq has not specified the date on which the Form 25-NSE will be filed. If Nasdaq has not filed the Form 25-NSE by March 20, 2024, the Company intends to file a Form 25 with the SEC on such date to remove the Class A Common Stock from listing and registration on Nasdaq. The Company plans to file a Form 15with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, shortly thereafter. The Company expects that its Class A Common Stock will be eligible to be quoted over-the-counter," however, no assurance can be given that quotation of the Class A Common Stock will be commenced or maintained on an over-the-counter market or any other quotation medium.New Risk • Feb 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$65m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$65m free cash flow). Share price has been highly volatile over the past 3 months (40% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€9.06m market cap, or US$9.75m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$51m net loss in 3 years).お知らせ • Feb 09Atreca, Inc. Announces Board ResignationsAtreca, Inc. announced tha Tito A. Serafini, Ph.D., ceased to serve as the Chief Strategy Officer of the Company, effective January 31, 2024. Dr. Serafini remains a member of the Board of Directors of the Company. In connection with the wind down of the operations of the Company, Stephen E. Gould, Ph.D., ceased to serve as the Chief Scientific Officer of the Company, effective December 31, 2023.Board Change • Nov 11Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 23Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial OfficerAtreca, Inc. announced that on September 15, 2023, Herbert Cross, Chief Financial Officer of the Company, resigned from his position, effective September 22, 2023, to pursue a new business opportunity. Mr. Cross' resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The Company thanks Mr. Cross for his contributions and wishes him well in his future endeavors. In connection with Mr. Cross’ resignation, John A. Orwin, Chief Executive Officer of the Company, was appointed to serve as the principal financial officer of the Company, effective as of the Separation Date.お知らせ • Sep 22Atreca, Inc. Appoints Rick Ruiz as the Principal Accounting OfficerAtreca, Inc. announced that In addition, in connection with Mr. Cross’ resignation, on September 17, 2023, the Board of Directors of the Company (the “Board”) approved the appointment of Rick Ruiz, Vice President of Finance of the Company, to serve as the principal accounting officer of the Company, effective as of the Separation Date. Mr. Ruiz, age 59, is an experienced financial professional with a demonstrated history of working in the biotechnology industry and extensive expertise in budgeting, accounting, corporate financial planning and analysis, and internal controls. Prior to his appointment as principal accounting officer of the Company, Mr. Ruiz served as the Company’s Vice President of Finance since September 2018. Prior to joining the Company, Mr. Ruiz served as a consultant at RoseRyan, Inc., a leading finance and accounting advisory firm from March 2014 to September 2018. Mr. Ruiz received a B.S. in Business, Accounting from Biola University.お知らせ • Sep 16Atreca Receives Notice from the Nasdaq Stock MarketOn September 8, 2023, Atreca, Inc. received notice from The Nasdaq Stock Market LLC notifying it that on September 7, 2023, the average closing price of the Company's Class A common stock, $0.0001 par value per share, over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the Minimum Bid Requirement, subject to a potential 180 calendar day extension. To regain compliance, the closing bid price of the Class A Common Stock must be at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period. If the Company does not achieve compliance with the Minimum Bid Requirement by March 6, 2024, the end of the Grace Period, it may be eligible for an additional 180 calendar day period to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. However, if it appears to Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company does not meet the other Nasdaq listing standards, Nasdaq could provide notice that the Class A Common Stock will be subject to delisting. In the event the Company receives notice that the Class A Common Stock is being delisted, the Company would be entitled to appeal the determination to a Nasdaq Listing Qualifications Panel and request a hearing. The Company intends to actively monitor the closing bid price of the Class A Common Stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Requirement or maintain compliance with the other listing requirements. The notice has no immediate effect on the listing or trading of the Class A Common Stock, which will continue to be listed and traded on Nasdaq, subject to the Company's compliance with the other Nasdaq listing standards.お知らせ • Aug 12Atreca, Inc. Reduces its Workforce by Approximately 40%Atreca, Inc. announced a corporate reorganization to reduce expenses and extend its cash runway. As part of the reorganization, Atreca will be undertaking cost-saving measures, including suspending development of ATRC-101 and reducing its workforce by approximately 40%. Going forward operations will focus on advancing current preclinical antibody-drug conjugate (ADC) candidates, including APN-497444, while preserving core discovery capabilities.お知らせ • Jun 06Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral AbstractAtreca, Inc. announced that Dr. Bartosz Chmielowski, Health Sciences Clinical Professor of Medicine in the Division of Hematology-Oncology at the University of California Los Angeles, presented safety and efficacy data from the ongoing Phase 1b study of ATRC-101 in patients with select advanced solid tumors cancer during an oral abstract session on Sunday, June 4 at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. The presentation provided a summary of clinical data collected as of a February 17, 2023, data cut-off date. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients.Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 10Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical OfficerAtreca, Inc. announced the appointment of Philippe Bishop, MD, as Chief Medical Officer, effective January 9, 2023. Dr. Bishop joins Atreca from Clover Biopharmaceuticals, a global biotech company focused on the development of vaccines and biologics, where he served as CMO. Previously, he was Executive Vice President and CMO at aratinga.bio, a developer of novel cancer immunotherapies. Before founding aratinga.bio in 2017, Dr. Bishop was Senior Vice President Hematology /Oncology at Gilead Sciences and held clinical development roles at Genentech, Johnson & Johnson and Sanofi-Aventis. Prior to his industry career, he held leadership positions at the U.S. Food and Drug Administration and National Institutes of Health. Dr. Bishop received his M.D. from the University of Nevada School of Medicine followed by a residency in internal medicine at the University of Washington School of Medicine and a medical oncology fellowship at the National Cancer Institute. In connection with Dr. Bishop’s appointment, Atreca granted Dr. Bishop an option to purchase 350,000 shares of Atreca Class A common stock with an exercise price based on the closing price per share of Atreca Class A common stock as reported on the Nasdaq Stock Market as of January 9, 2023, the effective date of the grant and the start date of Dr. Bishop’s employment. The option is a non-qualified stock option and vests over a period of four years, with 25% vesting on the one year anniversary of the grant date and the remaining 75% vesting on a monthly basis over three years, subject to Dr. Bishop’s continuous service through each vesting date. This award was granted as an inducement material to Dr. Bishop entering into employment with Atreca in accordance with Nasdaq Listing Rule 5635(c)(4).お知らせ • Jun 26Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 IndexAtreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Indexお知らせ • Jun 17Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific OfficerAtreca, Inc. announced the appointment of Stephen Gould, Ph.D., as Chief Scientific Officer. Dr. Gould is joining Atreca following 15 years at Genentech, where he held positions of increasing responsibility, most recently serving as Executive Director, Translational Oncology. At Genentech, Dr. Gould led a team focused on developing tumor specific antibodies weaponized with immune-targeting arms or drug payloads for use in both hematologic and solid tumors, including two approved medicines. Prior to joining Genentech, Dr. Gould served as Senior Director, Oncology at Curis. Dr. Gould received his Ph.D. from the University of Connecticut Health Center in Development Biology and held postdoctoral fellowships at the University of California San Francisco in the department of Orthopedic Surgery, and University of Virginia in the Department of Biology.お知らせ • May 05Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101Atreca, Inc. announced the peer-reviewed publication of preclinical data demonstrating how its lead product candidate, ATRC-101, activates the immune system and drives tumor destruction in a Proceedings of the National Academy of Sciences (PNAS) paper titled “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101.” The PNAS publication details the discovery and preclinical development of ATRC-101, which was identified via a target-agnostic process evaluating antibodies produced by the plasmablast population of B cells in a patient experiencing an antitumor immune response during treatment with checkpoint inhibitor therapy. Immunohistochemistry studies demonstrated tumor-selective binding of ATRC-101 to multiple non-autologous tumor tissues, and biochemical analyses indicate that it targets an extracellular, tumor-specific ribonucleoprotein (RNP) complex. Robust antitumor activity and evidence of immune memory following rechallenge with fresh tumor cells were observed in syngeneic murine models, as well as an influx of conventional dendritic cell (cDC) type 1 cells in the blood within 24 hours of dosing, increased CD8+ T cells and natural killer (NK) cells in blood and tumor over time, decreased cDC type 2 cells in the blood, and decreased monocytic myeloid-derived suppressor cells in the tumor. Cellular stress, including that induced by chemotherapy, increased the amount of ATRC-101 target in tumor cells, and ATRC-101 combined with doxorubicin enhanced efficacy compared with either agent alone.お知らせ • Apr 06Atreca, Inc. Provides an Update on Its Preclinical Pipeline in OncologyOn April 5, 2022, as part of its virtual R&D Day, Atreca, Inc. provided an update on its preclinical pipeline in oncology. In particular, the Company announced its next clinical candidate, ATRC-301. ATRC-301 is an ADC that selectively targets a novel, membrane-proximal epitope on erythropoietin-producing hepatocellular receptor A2. EphA2 is a validated and potentially high value target that is widely expressed across several types of cancer, with 12 tumor types displaying prevalence of the target epitope of 50% or greater in human tumor samples evaluated. ATRC-301 has demonstrated potent, dose-dependent in vivo tumor regression in mice with no significant toxicity signals yet observed in rats after single doses of up to and including 30mg/kg. The Company has initiated Investigational New Drug-enabling studies, including a non-human primate toxicology study for which data are expected in the second half of 2022, and the Company anticipates submitting an Investigational New Drug application for ATRC-301 in the second half of 2023. The Company also has a lead stage CD3-engager targeting EphA2 in development. The Company also announced that it is targeting one new IND application a year beginning with ATRC-301 in the second half of 2023.お知らせ • Jun 28+ 2 more updatesAtreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth IndexAtreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth IndexExecutive Departure • Apr 01Chief Scientific Officer has left the companyOn the 31st of March, Norman Greenberg's tenure as Chief Scientific Officer ended after 5.9 years in the role. As of December 2020, Norman personally held 5.00k shares (€63k worth at the time). A total of 2 executives have left over the last 12 months.お知らせ • Mar 12Atreca, Inc Announces Executive ChangesOn March 11, 2021, Atreca, Inc. announced that Tito A. Serafini, Ph.D., a founder, a director, and the Chief Strategy Officer of the Company, will lead business development activities at the Company, effective March 13, 2021. Lisa L. Decker, Ph.D., Chief Business Officer of the Company, will be resigning to pursue a new business opportunity, effective March 12, 2021. Dr. Decker’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.Executive Departure • Mar 12Chief Business Officer has left the companyOn the 12th of March, Lisa Decker's tenure as Chief Business Officer ended after 1.7 years in the role. We don't have any record of a personal shareholding under Lisa's name. Lisa is the only executive to leave the company over the last 12 months.Is New 90 Day High Low • Feb 17New 90-day high: €16.00The company is up 37% from its price of €11.70 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.Is New 90 Day High Low • Feb 02New 90-day low: €10.50The company is down 7.0% from its price of €11.30 on 03 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.Is New 90 Day High Low • Dec 16New 90-day high: €13.60The company is up 13% from its price of €12.00 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.お知らせ • Jul 17Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 7,031,250 Price\Range: $16 Security Name: Class B Common Stock Security Type: Common Stock Securities Offered: 781,250 Price\Range: $16業績と収益の成長予測DB:0C1 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2026N/A-52N/AN/A112/31/2025N/A-48N/AN/A112/31/2024N/A-38N/AN/A112/31/2023N/A-65N/AN/A19/30/2023N/A-98-65-65N/A6/30/2023N/A-85-65-64N/A3/31/2023N/A-93-71-70N/A12/31/2022N/A-97-82-81N/A9/30/2022N/A-105-86-81N/A6/30/2022N/A-110-88-81N/A3/31/2022N/A-108-93-69N/A12/31/2021N/A-109-96-61N/A9/30/2021N/A-103-96-63N/A6/30/2021N/A-98-93-62N/A3/31/2021N/A-92-82-66N/A12/31/2020N/A-86-72-67N/A9/30/2020N/A-83-70-65N/A6/30/2020N/A-76-71-65N/A3/31/2020N/A-74-67-63N/A12/31/2019N/A-67-62-59N/A9/30/2019N/A-59-56-53N/A6/30/2019N/A-53-47-45N/A3/31/2019N/A-44-41-40N/A12/31/2018N/A-38-36-35N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 0C1今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 0C1今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 0C1今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 0C1の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 0C1来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 0C1の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/06/25 22:17終値2024/03/28 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Atreca, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Michael UlzBairdKumaraguru RajaBrookline Capital MarketsJohn NewmanCanaccord Genuity8 その他のアナリストを表示
お知らせ • Jun 06Atreca, Inc. Announces Resignation of Franklin Berger from the BoardOn May 13, 2024, Mr. Franklin Berger resigned from the board of Atreca, Inc. Accordingly, Mr. Berger now serves on the boards of directors of three other public companies in addition to the Atea Board (Satellos Bioscience Inc., ESSA Pharma Inc., and Kezar Life Sciences, Inc.).
お知らせ • May 21Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) for $12.5 million on December 22, 2023. Pursuant to the agreement, Immunome will pay an aggregate purchase price of up to $12.5 million in cash, with $5.5 million due to the Atreca at the closing of the agreemeny and up to $7 million due upon the achievement of certain clinical-based milestone. The agreement have been unanimously approved by the board of directors of the Atreca. The agreement must also be approved by the Atreca’s stockholders, as a condition to the closing. In certain circumtances Atreca will pay a termination fee of $0.5 million to Immunome. Transaction is expected to close in the second quarter of 2024. John T. McKenna and Matthew Silverman of Cooley LLP acted as legal advisor to Atreca. Kingsley Taft and Steven Green of Goodwin Procter LLP acted as legal advisor to Immunome.Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) on May 20, 2024.
お知らせ • Apr 02Atreca, Inc. Files Form 15Atreca, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Class A Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Class A Common Stock was $0.0001 per share.
お知らせ • Mar 21Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI IndexAtreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index
お知らせ • Mar 19Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite IndexAtreca, Inc. has been dropped from NASDAQ Composite Index .
お知らせ • Mar 12Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid RequirementAs previously reported, on September 8, 2023, Atreca, Inc. (the Company") received written notification (the Initial Notice") from The Nasdaq Stock Market LLC (Nasdaq") notifying it that on September 7, 2023, the average closing price of the Company's Class A common stock, $0.0001 par value per share (the Class A Common Stock"), over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days from the date of the Initial Notice, or March 6, 2024, to regain compliance with the Minimum Bid Requirement (the Grace Period"), subject to a potential 180-day extension. To regain compliance, the closing bid price of the Class A Common Stock must have been at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period. On March 8, 2024, the Company received written notification from Nasdaq indicating that it had failed to achieve compliance with the Minimum Bid Requirement prior to the expiration of the Grace Period, and therefore the Class A Common Stock will be delisted from trading on Nasdaq. The Company does not intend to request an extension of the Grace Period or any administrative hearing to delay such delisting. As a result, the Class A Common Stock will be suspended from trading at the opening of business on March 19, 2024. Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission (the SEC") to remove the Class A Common Stock from listing and registration, though Nasdaq has not specified the date on which the Form 25-NSE will be filed. If Nasdaq has not filed the Form 25-NSE by March 20, 2024, the Company intends to file a Form 25 with the SEC on such date to remove the Class A Common Stock from listing and registration on Nasdaq. The Company plans to file a Form 15with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, shortly thereafter. The Company expects that its Class A Common Stock will be eligible to be quoted over-the-counter," however, no assurance can be given that quotation of the Class A Common Stock will be commenced or maintained on an over-the-counter market or any other quotation medium.
New Risk • Feb 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$65m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$65m free cash flow). Share price has been highly volatile over the past 3 months (40% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€9.06m market cap, or US$9.75m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$51m net loss in 3 years).
お知らせ • Feb 09Atreca, Inc. Announces Board ResignationsAtreca, Inc. announced tha Tito A. Serafini, Ph.D., ceased to serve as the Chief Strategy Officer of the Company, effective January 31, 2024. Dr. Serafini remains a member of the Board of Directors of the Company. In connection with the wind down of the operations of the Company, Stephen E. Gould, Ph.D., ceased to serve as the Chief Scientific Officer of the Company, effective December 31, 2023.
Board Change • Nov 11Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 23Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial OfficerAtreca, Inc. announced that on September 15, 2023, Herbert Cross, Chief Financial Officer of the Company, resigned from his position, effective September 22, 2023, to pursue a new business opportunity. Mr. Cross' resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The Company thanks Mr. Cross for his contributions and wishes him well in his future endeavors. In connection with Mr. Cross’ resignation, John A. Orwin, Chief Executive Officer of the Company, was appointed to serve as the principal financial officer of the Company, effective as of the Separation Date.
お知らせ • Sep 22Atreca, Inc. Appoints Rick Ruiz as the Principal Accounting OfficerAtreca, Inc. announced that In addition, in connection with Mr. Cross’ resignation, on September 17, 2023, the Board of Directors of the Company (the “Board”) approved the appointment of Rick Ruiz, Vice President of Finance of the Company, to serve as the principal accounting officer of the Company, effective as of the Separation Date. Mr. Ruiz, age 59, is an experienced financial professional with a demonstrated history of working in the biotechnology industry and extensive expertise in budgeting, accounting, corporate financial planning and analysis, and internal controls. Prior to his appointment as principal accounting officer of the Company, Mr. Ruiz served as the Company’s Vice President of Finance since September 2018. Prior to joining the Company, Mr. Ruiz served as a consultant at RoseRyan, Inc., a leading finance and accounting advisory firm from March 2014 to September 2018. Mr. Ruiz received a B.S. in Business, Accounting from Biola University.
お知らせ • Sep 16Atreca Receives Notice from the Nasdaq Stock MarketOn September 8, 2023, Atreca, Inc. received notice from The Nasdaq Stock Market LLC notifying it that on September 7, 2023, the average closing price of the Company's Class A common stock, $0.0001 par value per share, over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the Minimum Bid Requirement, subject to a potential 180 calendar day extension. To regain compliance, the closing bid price of the Class A Common Stock must be at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period. If the Company does not achieve compliance with the Minimum Bid Requirement by March 6, 2024, the end of the Grace Period, it may be eligible for an additional 180 calendar day period to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. However, if it appears to Nasdaq staff that the Company will not be able to cure the deficiency, or if the Company does not meet the other Nasdaq listing standards, Nasdaq could provide notice that the Class A Common Stock will be subject to delisting. In the event the Company receives notice that the Class A Common Stock is being delisted, the Company would be entitled to appeal the determination to a Nasdaq Listing Qualifications Panel and request a hearing. The Company intends to actively monitor the closing bid price of the Class A Common Stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Requirement or maintain compliance with the other listing requirements. The notice has no immediate effect on the listing or trading of the Class A Common Stock, which will continue to be listed and traded on Nasdaq, subject to the Company's compliance with the other Nasdaq listing standards.
お知らせ • Aug 12Atreca, Inc. Reduces its Workforce by Approximately 40%Atreca, Inc. announced a corporate reorganization to reduce expenses and extend its cash runway. As part of the reorganization, Atreca will be undertaking cost-saving measures, including suspending development of ATRC-101 and reducing its workforce by approximately 40%. Going forward operations will focus on advancing current preclinical antibody-drug conjugate (ADC) candidates, including APN-497444, while preserving core discovery capabilities.
お知らせ • Jun 06Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral AbstractAtreca, Inc. announced that Dr. Bartosz Chmielowski, Health Sciences Clinical Professor of Medicine in the Division of Hematology-Oncology at the University of California Los Angeles, presented safety and efficacy data from the ongoing Phase 1b study of ATRC-101 in patients with select advanced solid tumors cancer during an oral abstract session on Sunday, June 4 at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. The presentation provided a summary of clinical data collected as of a February 17, 2023, data cut-off date. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients.
Board Change • Jun 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 10Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical OfficerAtreca, Inc. announced the appointment of Philippe Bishop, MD, as Chief Medical Officer, effective January 9, 2023. Dr. Bishop joins Atreca from Clover Biopharmaceuticals, a global biotech company focused on the development of vaccines and biologics, where he served as CMO. Previously, he was Executive Vice President and CMO at aratinga.bio, a developer of novel cancer immunotherapies. Before founding aratinga.bio in 2017, Dr. Bishop was Senior Vice President Hematology /Oncology at Gilead Sciences and held clinical development roles at Genentech, Johnson & Johnson and Sanofi-Aventis. Prior to his industry career, he held leadership positions at the U.S. Food and Drug Administration and National Institutes of Health. Dr. Bishop received his M.D. from the University of Nevada School of Medicine followed by a residency in internal medicine at the University of Washington School of Medicine and a medical oncology fellowship at the National Cancer Institute. In connection with Dr. Bishop’s appointment, Atreca granted Dr. Bishop an option to purchase 350,000 shares of Atreca Class A common stock with an exercise price based on the closing price per share of Atreca Class A common stock as reported on the Nasdaq Stock Market as of January 9, 2023, the effective date of the grant and the start date of Dr. Bishop’s employment. The option is a non-qualified stock option and vests over a period of four years, with 25% vesting on the one year anniversary of the grant date and the remaining 75% vesting on a monthly basis over three years, subject to Dr. Bishop’s continuous service through each vesting date. This award was granted as an inducement material to Dr. Bishop entering into employment with Atreca in accordance with Nasdaq Listing Rule 5635(c)(4).
お知らせ • Jun 26Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 IndexAtreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index
お知らせ • Jun 17Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific OfficerAtreca, Inc. announced the appointment of Stephen Gould, Ph.D., as Chief Scientific Officer. Dr. Gould is joining Atreca following 15 years at Genentech, where he held positions of increasing responsibility, most recently serving as Executive Director, Translational Oncology. At Genentech, Dr. Gould led a team focused on developing tumor specific antibodies weaponized with immune-targeting arms or drug payloads for use in both hematologic and solid tumors, including two approved medicines. Prior to joining Genentech, Dr. Gould served as Senior Director, Oncology at Curis. Dr. Gould received his Ph.D. from the University of Connecticut Health Center in Development Biology and held postdoctoral fellowships at the University of California San Francisco in the department of Orthopedic Surgery, and University of Virginia in the Department of Biology.
お知らせ • May 05Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101Atreca, Inc. announced the peer-reviewed publication of preclinical data demonstrating how its lead product candidate, ATRC-101, activates the immune system and drives tumor destruction in a Proceedings of the National Academy of Sciences (PNAS) paper titled “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101.” The PNAS publication details the discovery and preclinical development of ATRC-101, which was identified via a target-agnostic process evaluating antibodies produced by the plasmablast population of B cells in a patient experiencing an antitumor immune response during treatment with checkpoint inhibitor therapy. Immunohistochemistry studies demonstrated tumor-selective binding of ATRC-101 to multiple non-autologous tumor tissues, and biochemical analyses indicate that it targets an extracellular, tumor-specific ribonucleoprotein (RNP) complex. Robust antitumor activity and evidence of immune memory following rechallenge with fresh tumor cells were observed in syngeneic murine models, as well as an influx of conventional dendritic cell (cDC) type 1 cells in the blood within 24 hours of dosing, increased CD8+ T cells and natural killer (NK) cells in blood and tumor over time, decreased cDC type 2 cells in the blood, and decreased monocytic myeloid-derived suppressor cells in the tumor. Cellular stress, including that induced by chemotherapy, increased the amount of ATRC-101 target in tumor cells, and ATRC-101 combined with doxorubicin enhanced efficacy compared with either agent alone.
お知らせ • Apr 06Atreca, Inc. Provides an Update on Its Preclinical Pipeline in OncologyOn April 5, 2022, as part of its virtual R&D Day, Atreca, Inc. provided an update on its preclinical pipeline in oncology. In particular, the Company announced its next clinical candidate, ATRC-301. ATRC-301 is an ADC that selectively targets a novel, membrane-proximal epitope on erythropoietin-producing hepatocellular receptor A2. EphA2 is a validated and potentially high value target that is widely expressed across several types of cancer, with 12 tumor types displaying prevalence of the target epitope of 50% or greater in human tumor samples evaluated. ATRC-301 has demonstrated potent, dose-dependent in vivo tumor regression in mice with no significant toxicity signals yet observed in rats after single doses of up to and including 30mg/kg. The Company has initiated Investigational New Drug-enabling studies, including a non-human primate toxicology study for which data are expected in the second half of 2022, and the Company anticipates submitting an Investigational New Drug application for ATRC-301 in the second half of 2023. The Company also has a lead stage CD3-engager targeting EphA2 in development. The Company also announced that it is targeting one new IND application a year beginning with ATRC-301 in the second half of 2023.
お知らせ • Jun 28+ 2 more updatesAtreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth IndexAtreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index
Executive Departure • Apr 01Chief Scientific Officer has left the companyOn the 31st of March, Norman Greenberg's tenure as Chief Scientific Officer ended after 5.9 years in the role. As of December 2020, Norman personally held 5.00k shares (€63k worth at the time). A total of 2 executives have left over the last 12 months.
お知らせ • Mar 12Atreca, Inc Announces Executive ChangesOn March 11, 2021, Atreca, Inc. announced that Tito A. Serafini, Ph.D., a founder, a director, and the Chief Strategy Officer of the Company, will lead business development activities at the Company, effective March 13, 2021. Lisa L. Decker, Ph.D., Chief Business Officer of the Company, will be resigning to pursue a new business opportunity, effective March 12, 2021. Dr. Decker’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
Executive Departure • Mar 12Chief Business Officer has left the companyOn the 12th of March, Lisa Decker's tenure as Chief Business Officer ended after 1.7 years in the role. We don't have any record of a personal shareholding under Lisa's name. Lisa is the only executive to leave the company over the last 12 months.
Is New 90 Day High Low • Feb 17New 90-day high: €16.00The company is up 37% from its price of €11.70 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.
Is New 90 Day High Low • Feb 02New 90-day low: €10.50The company is down 7.0% from its price of €11.30 on 03 November 2020. The German market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.
Is New 90 Day High Low • Dec 16New 90-day high: €13.60The company is up 13% from its price of €12.00 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
お知らせ • Jul 17Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million. Security Name: Class A Common Stock Security Type: Common Stock Securities Offered: 7,031,250 Price\Range: $16 Security Name: Class B Common Stock Security Type: Common Stock Securities Offered: 781,250 Price\Range: $16